Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178335 | 0.85 | P2RX7 (0.42) | P2RX7ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL27615010 | 0.79 | P2RX7 (0.42) | P2RX7MKNK1MKNK2FFAR1 | |
| SCHEMBL27707669 | 0.79 | P2RX7 (0.42) | P2RX7MKNK1MKNK2FFAR1 | |
| SCHEMBL666127 | 0.77 | PLAU (0.40) | P2RX7MKNK1MKNK2ALDH1A1LMNA | |
| SCHEMBL2030601 | 0.76 | ALDH1A1 (0.44) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL2431567 | 0.75 | P2RX7 (0.36) | P2RX7ALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL28336015 | 0.74 | LMNA (0.41) | P2RX7MKNK1MKNK2ALDH1A1LMNA | |
| SCHEMBL17681956 | 0.74 | LMNA (0.41) | P2RX7MKNK1MKNK2ALDH1A1LMNA | |
| SCHEMBL30608837 | 0.74 | P2RX7 (0.40) | P2RX7MKNK1MKNK2LMNASMN1; SMN2 | |
| SCHEMBL17681986 | 0.74 | LMNA (0.41) | P2RX7MKNK1MKNK2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELI LILLY AND COMPANY (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2018-09-20 | — | — | US | disclosed |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | HYDRA BIOSCIENCES, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | ELI LILLY AND COMPANY | 2012-02-23 | — | — | US | disclosed |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELANE, CASP3, MMP8 | P2RX7 2246/4885MKNK1 1821/4885MKNK2 2214/4885 |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | P2RX7 47/4885MKNK1 3931/4885MKNK2 3444/4885 |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | P2RX7 2246/4885MKNK1 1821/4885MKNK2 2214/4885 |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | P2RX7 47/4885MKNK1 3931/4885MKNK2 3444/4885 |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | TRPA1, TRPV1, TRPV3 | P2RX7 35/4885MKNK1 4393/4885MKNK2 4208/4885 |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | P2RX7 2246/4885MKNK1 1821/4885MKNK2 2214/4885 |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | P2RX7 47/4885MKNK1 3931/4885MKNK2 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.